Core Viewpoint - On January 8, a total of 8 companies announced progress related to stock buybacks, with 5 companies disclosing ongoing buyback implementations and 3 companies completing their buyback plans [1] Group 1: Buyback Implementation Progress - The companies with the highest buyback amounts are Jian Sheng Group, Dongcheng Pharmaceutical, and Minsheng Health, with buybacks of 118 million, 17.1863 million, and 14.9993 million respectively [1] - As of January 8, 29 buyback plans have been completed this year, involving 22 companies, with 7 companies having completed buybacks exceeding 100 million [1] Group 2: Completed Buybacks - The companies that completed buybacks exceeding 10 million on that day are Jingxin Pharmaceutical, Huachangda, and Shibu Detection, with completed buybacks of 609 million, 41.8996 million, and 31.9512 million respectively [1] - The leading companies in terms of completed buyback amounts are BOE Technology Group, Jingxin Pharmaceutical, and New Hualian, with completed buybacks of 1.5 billion, 609 million, and 556 million respectively [1]

Core Viewpoint - The company has approved a share repurchase plan aimed at using its own funds to buy back shares for employee stock ownership plans and equity incentives, with a total repurchase amount adjusted to between RMB 35 million and RMB 70 million [2] Group 1: Share Repurchase Plan - The initial share repurchase plan was set for a total amount of no less than RMB 20 million and no more than RMB 40 million, with a maximum repurchase price of RMB 14.80 per share, allowing for an estimated repurchase of approximately 13.51 million to 27.03 million shares [1] - The total repurchase amount was later adjusted to a range of RMB 35 million to RMB 70 million, while other aspects of the repurchase plan remained unchanged [2] - The maximum repurchase price was subsequently adjusted to RMB 14.47 per share, allowing for an estimated repurchase of approximately 24.19 million to 48.38 million shares [3] Group 2: Implementation Status - As of the announcement date, the company completed the share repurchase plan, having repurchased a total of 47.27 million shares, which is 5.49% of the total share capital, with a total expenditure of RMB 608.72 million [4] - The highest purchase price during the repurchase was RMB 14.41 per share, and the lowest was RMB 11.86 per share [4] - The company confirmed that the actual repurchase funds exceeded the lower limit of the initial plan but did not exceed the upper limit, and the repurchase price remained within the set limits [5] Group 3: Compliance and Future Arrangements - The share repurchase was conducted in compliance with relevant regulations, ensuring that no shares were repurchased during periods that could significantly impact stock prices [6] - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period [7] - If the shares are not utilized for the intended purposes within 36 months, the unused portion will be canceled following legal procedures [7]

Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) has completed its share repurchase program, acquiring a total of 47.27 million shares, which represents 5.49% of the company's total share capital [1] Summary by Categories Share Repurchase Details - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest purchase price for the shares was 14.41 CNY per share, while the lowest was 11.86 CNY per share [1] - The total amount spent on the repurchase was 608.72 million CNY, excluding transaction fees [1] Compliance and Strategy - The share repurchase complies with relevant laws and regulations [1] - The repurchase aligns with the company's established share repurchase plan [1]

每经AI快讯，京新药业1月7日晚间发布公告称，截至本报告披露日，公司回购股份期限已届满。公司 累计通过股份回购专用证券账户以集中竞价方式回购公司股份4,727.1295万股，占公司目前总股本的 5.49%，购买股份最高成交价为14.41元/股，购买股份最低成交价为11.86元/股，成交总金额为60,872.22 万元（不含交易费用）。本次回购符合相关法律法规的要求，符合公司既定的回购股份方案。 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 （记者 曾健辉） ...

浙江京新药业股份有限公司（以下简称"公司"）于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元（含），不超过人民 币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年1月10日在《证券时报》《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于回购股份方案的公告》（公告编号：2025002）、《回购报告书》 （公告编号：2025003）。 证券代码：002020 证券简称：京新药业 公告编号：202600 ...

京新药业公告称，截至公告披露日，公司回购股份期限已届满，方案实施完毕。此次回购资金为自有资 金，累计回购股份4727.1295万股，占公司目前总股本的5.49%，成交总金额为6.09亿元（不含交易费 用），购买股份最高成交价为14.41元/股，最低成交价为11.86元/股。本次回购符合相关规定，股份将 用于股权激励或员工持股计划，若未使用将依法注销。 ...

Group 1 - The core viewpoint of the news is that Jingxin Pharmaceutical has shown a positive stock performance with a 5.22% increase year-to-date and a market capitalization of 17.195 billion yuan as of January 7 [1] - As of January 7, the stock price reached 19.97 yuan per share, with a trading volume of 1.28 billion yuan and a turnover rate of 0.89% [1] - The company has a main business revenue composition of 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1] Group 2 - As of September 30, the number of shareholders for Jingxin Pharmaceutical decreased by 13.08% to 22,300, while the average circulating shares per person increased by 15.05% to 32,438 shares [2] - For the period from January to September 2025, Jingxin Pharmaceutical reported a revenue of 3.048 billion yuan, a decrease of 5.00% year-on-year, while the net profit attributable to the parent company was 576 million yuan, reflecting a slight increase of 0.10% [2] - The company has distributed a total of 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

证券代码：002020 证券简称：京新药业 公告编号：2026001 浙江京新药业股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 ...